Alkermes (ALKS) EBITDA (2010 - 2026)

Alkermes (ALKS) has 17 years of EBITDA data on file, last reported at -$48.3 million in Q1 2026.

• On a quarterly basis, EBITDA fell 450.06% year-over-year to -$48.3 million in Q1 2026; TTM through Mar 2026 was $191.9 million, a 50.94% decrease from a year earlier, with the FY2025 full-year figure at $254.0 million, down 39.63% from the prior year.
• EBITDA for Q1 2026 stood at -$48.3 million, down from $58.1 million in the prior quarter.
• Over the last five years, EBITDA for ALKS reached as high as $281.3 million in Q2 2023 and fell as low as -$60.6 million in Q3 2022.
• Historically, EBITDA has averaged $60.8 million across 5 years, with a median of $58.1 million in 2025.
• Across the five-year window, EBITDA tumbled 879.39% in 2022 and jumped 916.29% in 2023, its largest moves.
• Year by year, EBITDA stood at $115.6 million in 2022, then slumped by 52.74% to $54.6 million in 2023, then soared by 197.79% to $162.7 million in 2024, then slumped by 64.29% to $58.1 million in 2025, then slumped by 183.09% to -$48.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$48.3 million in Q1 2026, $58.1 million in Q4 2025, and $89.1 million in Q3 2025.